NuCana to Present Preclinical Data on NUC-7738 and PD-1 Inhibitor Combination at ESMO 2025
核心洞察
NuCana (搜索) will present preclinical data demonstrating synergy between NUC-7738 and PD-1 (搜索) inhibitors in renal cell cancer (搜索) using patient-derived organoids at ESMO Congress 2025.
The presentation will be delivered on October 19, 2025, in Berlin as part of the Investigational Immunotherapy session.
NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation (搜索) and is currently in Phase 2 trials as monotherapy and in combination with pembrolizumab for melanoma (搜索) patients.
NuCana (搜索) plc announced it will present preclinical data on the synergistic effects of its investigational drug NUC-7738 combined with PD-1 (搜索) inhibitors in renal cell cancer (搜索) at the European Society for Medical Oncology (ESMO) Congress 2025. The presentation, scheduled for October 19, 2025, in Berlin, will showcase findings from patient-derived organoid studies that demonstrate enhanced therapeutic potential when combining these treatment modalities.
Novel Mechanism of Action Shows Promise in Combination Therapy
The upcoming presentation, titled "Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 (搜索) Inhibition in Renal Cell Cancer (搜索)," will be delivered by H. Abdullah during the Investigational Immunotherapy session. The research utilizes patient-derived organoids, which provide a more clinically relevant model system for evaluating drug combinations compared to traditional cell culture methods.
NUC-7738 represents a novel approach to cancer treatment through its unique mechanism of action. The drug disrupts RNA polyadenylation (搜索), which profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. This mechanism distinguishes NUC-7738 from conventional chemotherapy agents and may explain its potential synergy with immunotherapy approaches.
Current Clinical Development Program
NUC-7738 is currently being evaluated in the Phase 2 portion of a Phase 1/2 clinical study. The trial is assessing NUC-7738 both as a monotherapy in patients with advanced solid tumors (搜索) and in combination with pembrolizumab, a PD-1 (搜索) inhibitor, specifically in melanoma (搜索) patients. This clinical program demonstrates NuCana (搜索)'s commitment to exploring combination strategies that could enhance treatment outcomes.
The company's approach builds on its proprietary ProTide technology platform, which transforms widely prescribed nucleoside analog chemotherapy agents into more effective and safer medicines. According to NuCana (搜索), conventional nucleoside analogs remain part of standard care for many solid and hematological tumors but have significant limitations that restrict their efficacy and tolerability.
Broader Pipeline Development
Beyond NUC-7738, NuCana (搜索)'s pipeline includes NUC-3373, a new chemical entity derived from 5-fluorouracil. NUC-3373 is currently being evaluated in a Phase 1b/2 modular study called NuTide:303, which examines the drug in combination with pembrolizumab for advanced solid tumors (搜索) and with docetaxel for lung cancer (搜索) patients.
The ESMO Congress 2025 presentation represents an important milestone for NuCana (搜索) as it continues to build evidence for combination approaches in oncology. The abstract will be published online via the ESMO website on October 13 at 6:05 p.m. ET, providing the broader oncology community with access to the detailed findings ahead of the congress presentation.